A lack of data and varying efficacy rates reported for the vaccine from different countries could undermine public trust in the rollout, according to public health experts. To start, only three million doses of CoronaVac will be available in Indonesia. Some 1.2 million doses have been dispatched to 34 provinces, which span an area wider than the continental United States. Sinovac has been overseeing late-stage clinical trials in Indonesia along with local state-owned drugmaker Bio Farma. But public health workers report scepticism, particularly given that it is the first major international campaign using the Sinovac vaccine.

Source: bd News24 January 11, 2021 09:56 UTC